Table 4.
Distributions of continuous parameters in relation to linezolid target ranges
| |
Median and range of patients |
|||||
|---|---|---|---|---|---|---|
| |
AUC
24
(mg*h/L)
a
|
C
min
(mg/L)
b
|
||||
| Patient groups | <200 | 200 to 400 | >400 | <2 | 2 to 10 | >10 |
| Mean creatinine clearance (mL/minute)c | ||||||
| median |
89 |
62 |
|
89 |
70 |
|
| range |
35 to 163 |
21 to 117 |
|
35 to 163 |
21 to 117 |
|
| (number of patients) |
(17) |
(8) |
|
(15) |
(10) |
|
| APACHE II score | ||||||
| median |
28 |
24 |
32 |
28 |
24 |
32 |
| range |
12 to 37 |
9 to 33 |
28 to 35 |
12 to 37 |
9 to 33 |
28 to 35 |
| (number of patients) |
(19) |
(9) |
(2) |
(15) |
(13) |
(2) |
| Age (years) | ||||||
| median |
53 |
59 |
56 |
57 |
57 |
56 |
| range |
28 to 77 |
34 to 84 |
50 to 61 |
28 to 77 |
29 to 84 |
50 to 61 |
| (number of patients) |
(19) |
(9) |
(2) |
(15) |
(13) |
(2) |
| Body mass index (kg/m2) | ||||||
| median |
24 |
19 |
21 |
22 |
23 |
21 |
| range |
13 to 32 |
17 to 26 |
19 to 23 |
13 to 32 |
17 to 28 |
19 to 23 |
| (number of patients) | (19) | (9) | (2) | (15) | (13) | (2) |
aAs determined by the NONMEM system, values from the start of the third administration of linezolid; bas determined by liquid chromatography tandem mass spectrometry, values obtained directly before the fourth administration of linezolid; cmean value of the 4 study days. AUC24, concentration time curve over 24 h; Cmin, linezolid trough level; APACHE II, acute physiology and chronic health evaluation II.